Welcome to our dedicated page for UCB SA UNSP/ADR news (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on UCB SA UNSP/ADR stock.
UCB SA UNSP/ADR (UCBJY) is a global biopharmaceutical company focused on developing innovative medicines for immune system and central nervous system diseases. Recent achievements include 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies for hidradenitis suppurativa patients, showing clinically meaningful improvements in skin pain and draining tunnels with BIMZELX treatment. The company is actively pursuing regulatory applications globally for the approval of BIMZELX.
Rhea-AI Summary
UCB reports FY 2023 revenue of €5.25 billion, net sales of €4.87 billion, and strong performance by growth drivers. The company achieved a 7% increase in adjusted EBITDA, with financial guidance for 2024 projecting revenue growth to €5.5-5.7 billion. UCB's CEO highlights the company's commitment to patient access and sustainability efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
-
Rhea-AI Summary
UCB Announces Commercial Availability of ZILBRYSQ (zilucoplan) in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-AChR Antibody Positive
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
-
Rhea-AI Summary
Study on Zogenix Inc. (ZGNX) FINTEPLA Shows Positive Efficacy and Tolerability Over 12 Months
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
UCB, a global biopharmaceutical company, will present 29 abstracts, including 4 late breakers, at the American Epilepsy Society Annual Meeting 2023. The presentations will highlight clinical, health economic, and demographic studies in epilepsy, demonstrating the diversity, potential, and momentum of UCB's epilepsy and rare syndromes portfolio, including important fenfluramine and brivaracetam data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
-
Rhea-AI Summary
UCB - BIMZELX® (bimekizumab-bkzx) is now commercially available by prescription in the United States. It is the first and only IL-17A and IL-17F inhibitor approved for treating adults with moderate-to-severe plaque psoriasis. BIMZELX Navigate™, a personalized patient support system, is also available to eligible patients to provide support during treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
-
Rhea-AI Summary
UCB: Post Hoc Analysis Reveals CIMZIA's Efficacy in RA Patients with High RF Levels
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
UCB - New BIMZELX Phase 2b Study Data Shows Sustained Improvements in Ankylosing Spondylitis Patients, Presented at ACR Convergence 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
UCB will be presenting results from its portfolio in generalized myasthenia gravis (gMG) at the AANEM annual meeting and the MGFA Scientific Session. The presentations will include data from the MycarinG and RAISE studies, as well as real-world MG data. UCB's rozanolixizumab-noli and zilucoplan have received regulatory approvals for the treatment of gMG in adult patients. UCB will also host a symposium on navigating the new treatment landscape for gMG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary
UCB, a global biopharmaceutical company, announced that a post hoc analysis from the Phase 3 open-label extension study of NAYZILAM showed that the median time to return to full baseline function (RTFBF) after using the nasal spray for seizure clusters was 90 minutes. The analysis revealed that the time to RTFBF was stable over the course of repeated, intermittent use. NAYZILAM is a nasal treatment for seizure clusters in people 12 years of age or older, approved by the FDA in 2019.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
Rhea-AI Summary
The US FDA has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. BIMZELX is the first and only approved psoriasis treatment designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
FAQ
What is the current stock price of UCB SA UNSP/ADR (UCBJY)?
The current stock price of UCB SA UNSP/ADR (UCBJY) is $99.972 as of December 23, 2024.
What is the market cap of UCB SA UNSP/ADR (UCBJY)?
The market cap of UCB SA UNSP/ADR (UCBJY) is approximately 37.0B.
What is UCB SA UNSP/ADR known for?
UCB SA UNSP/ADR, with the symbol UCBJY, is a renowned global biopharmaceutical company dedicated to developing innovative medicines for patients with severe immune system and central nervous system diseases.
What are the recent achievements of UCBJY?
The company recently shared 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies, showcasing the impact of BIMZELX on hidradenitis suppurativa patients' skin pain and draining tunnels.
What regulatory milestones have UCBJY achieved recently?
UCB has announced that the FDA accepted a supplemental Biologics License Application (sBLA) for BIMZELX for the treatment of moderate-to-severe hidradenitis suppurativa (HS), along with a second sBLA for BIMZELX 2mL device presentations.
What is the status of BIMZELX approval in the U.S.?
BIMZELX is currently approved in the U.S. for moderate-to-severe plaque psoriasis in adults and is under regulatory review for moderate-to-severe HS, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
What are the key secondary endpoints of the BE HEARD I and BE HEARD II studies?
The primary endpoint of both trials was HiSCR50 at Week 16, with a key secondary endpoint being HiSCR75 at Week 16, defined as a 50 or 75 percent reduction from baseline in total abscess and inflammatory nodule count.
UCB SA UNSP/ADR